pith. sign in

arxiv: 2605.22637 · v1 · pith:G4CAGF2Enew · submitted 2026-05-21 · 💻 cs.ET

Whole-Blood Boundary Analysis of BioFET-Based ctDNA Detection for Intravascular Sensing in Intrabody Nanonetworks

Ida Kleger-Rudomin , Filip Lemic , Sergi Abadal , Eduard Alarcon , Ethungshan Shitiri This is my paper

Pith reviewed 2026-05-22 03:59 UTC · model grok-4.3

classification 💻 cs.ET
keywords BioFETctDNA detectionwhole bloodintravascular sensingintrabody nanonetworksstochastic simulationDebye screeningcharge gating
0
0 comments X

The pith

Simulations indicate BioFET ctDNA sensors do not reliably exceed blank thresholds at low concentrations in whole blood.

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The paper builds a reduced-order stochastic simulation to check whether BioFET nanosensors can detect ctDNA in whole blood for use inside the body via nanonetworks. It connects charge gating, Debye screening, binding kinetics, nonspecific adsorption, background fluctuations, and device noise to a blank-derived detection threshold. Monte Carlo runs with realistic blood parameters show that current shifts from low ctDNA levels stay too small to cross that threshold reliably under quasi-static operation. A reader would care because this sets practical limits on whether label-free intravascular sensing can work without redesigning the sensor-blood interface.

Core claim

Under the tested quasi-static charge-gating regime, the simulated current shifts do not reliably exceed the blank-derived threshold at low ctDNA concentrations. The model therefore supplies a whole-blood boundary analysis that identifies which interface configurations and operating conditions most strongly limit reliable BioFET-based intravascular ctDNA detection.

What carries the argument

Reduced-order stochastic simulation model linking Debye-screened charge transduction, stochastic finite-capacity binding, nonspecific adsorption, background fluctuations, and intrinsic electronic noise to blank-threshold detection.

If this is right

  • Short Debye length and several-nanometer charge-to-channel separation strongly attenuate the observable current shift.
  • Low-frequency noise and background fluctuations shrink the separation between target-present and blank response distributions.
  • Reliable detection therefore depends on choosing interface configurations and operating conditions that maximize signal margin over the blank threshold.

Where Pith is reading between the lines

These are editorial extensions of the paper, not claims the author makes directly.

  • If the model holds, intravascular nanonetwork designs may need to incorporate surface modifications that extend effective Debye length or reduce separation distance.
  • The boundary analysis points to possible value in testing non-quasi-static or frequency-selective gating schemes to improve margin against noise.
  • This work suggests hybrid sensing approaches that combine BioFETs with other modalities when whole-blood conditions dominate.

Load-bearing premise

The reduced-order stochastic simulation model with physiologically grounded parameters accurately captures the combined effects of Debye-screened charge transduction, stochastic finite-capacity binding, nonspecific adsorption, background fluctuations, and intrinsic electronic noise in whole blood.

What would settle it

A direct measurement of current-shift distributions in whole blood at low ctDNA concentrations compared against blank thresholds; reliable exceedance in experiment would falsify the simulation-based claim.

Figures

Figures reproduced from arXiv: 2605.22637 by Eduard Alarcon, Ethungshan Shitiri, Filip Lemic, Ida Kleger-Rudomin, Sergi Abadal.

Figure 1
Figure 1. Figure 1: Whole-blood ctDNA sensing in an intrabody nanonetwork compared with conventional liquid biopsy. [PITH_FULL_IMAGE:figures/full_fig_p002_1.png] view at source ↗
Figure 2
Figure 2. Figure 2: BioFET stack and whole-blood background modeled [PITH_FULL_IMAGE:figures/full_fig_p003_2.png] view at source ↗
Figure 3
Figure 3. Figure 3: isolates screening-limited signal formation at 𝐶𝑡 = 0.1 aM. For all three interface thicknesses, |Δ𝐼𝐷 | increases with 𝜆𝐷 because weaker screening allows more bound charge to modulate the chan￾nel. The separation among the curves shows that biofunctional￾layer thickness strongly controls signal size. Increasing 𝑑𝑏 from 5 nm to 7 nm and 9 nm reduces the current shift by about one to two orders of magnitude … view at source ↗
Figure 4
Figure 4. Figure 4: translates that signal trend into detection performance. Sensitivity increases sharply with 𝜆𝐷 , but only at sufficiently high target concentration. At 1 fM, sensitivity rises from about 30% at 𝜆𝐷 = 0.7 nm to near 100% once 𝜆𝐷 reaches about 0.8 to 0.9 nm. At 100 aM, sensitivity remains near 10% to 15%. At 10 aM, sensitivity stays close to zero. This pattern shows a threshold-like operat￾ing transition. Hig… view at source ↗
Figure 5
Figure 5. Figure 5: shows how oxide scaling depends on biofunctional-layer thickness under strong screening with 𝜆𝐷 = 0.7 nm. For 𝑑𝑏 = 5 nm, reducing 𝑡ox mainly improves the 1 fM case. Sensitivity falls from near 100% at 𝑡ox = 2 nm to about 10% to 15% at 𝑡ox = 5 nm, while 100 aM and 10 aM remain low across the sweep. For 𝑑𝑏 = 7 nm, sensitivity drops sharply across all three concentrations. The comparison between [PITH_FULL_I… view at source ↗
Figure 7
Figure 7. Figure 7: shows that specificity stays near 90% to 93% across the oxide-thickness sweep. The blank-derived threshold therefore con￾trols false positives in the modeled geometry range. The main loss appears instead as missed detections at low target concentration, where target-present shifts do not consistently exceed the blank floor. This pattern is consistent with the detector definition in Sec￾tion 2.4, where 𝜃 is… view at source ↗
Figure 8
Figure 8. Figure 8: shows the electronic noise floor used in the detection model. The thermal component is nearly flat across frequency, whereas the 1/𝑓 component is much larger at low frequency and decreases gradually with frequency. Because the model uses a quasi-static low￾frequency regime, flicker noise dominates most of the measurement band. This explains why weak screened signals remain difficult to detect. After screen… view at source ↗
read the original abstract

Liquid biopsy can detect tumor-derived biomarkers such as circulating tumor DNA (ctDNA), but ultra-low-fraction assays remain costly, slow, and difficult to scale. This motivates interest in intravascular in vivo sensing in the context of intrabody nanonetworks, where nanosensors could support local biomarker monitoring. BioFET-based nanosensors are relevant here because they are label-free, highly miniaturizable, and have shown strong ctDNA sensitivity in controlled media. We examine whether this sensitivity still yields reliable ctDNA detection in whole blood using a reduced-order stochastic simulation model that links operating-point selection, Debye-screened charge transduction, stochastic finite-capacity binding, nonspecific adsorption, background fluctuations, and intrinsic electronic noise to blank-threshold detection. Monte Carlo evaluation with physiologically grounded parameters shows that short Debye length and several-nanometer charge-to-channel separation attenuate the current shift, while low-frequency noise and background fluctuations reduce the margin between target-present and blank responses. Under the tested quasi-static charge-gating regime, the simulated current shifts do not reliably exceed the blank-derived threshold at low ctDNA concentrations. The model therefore provides a whole-blood boundary analysis that identifies which interface configurations and operating conditions most strongly limit reliable BioFET-based intravascular ctDNA detection.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, simulated authors' rebuttal, and a circularity audit. Tearing a paper down is the easy half of reading it; the pith above is the substance, this is the friction.

Referee Report

1 major / 2 minor

Summary. The manuscript develops a reduced-order stochastic simulation model for BioFET-based ctDNA detection in whole blood for intravascular sensing in intrabody nanonetworks. The model integrates operating-point selection, Debye-screened charge transduction, stochastic finite-capacity binding, nonspecific adsorption, background fluctuations, and intrinsic electronic noise. Monte Carlo evaluation with physiologically grounded parameters under a quasi-static charge-gating regime shows that short Debye length and several-nanometer charge-to-channel separation attenuate the current shift, while low-frequency noise and background fluctuations reduce the margin between target and blank responses, such that simulated current shifts do not reliably exceed the blank-derived threshold at low ctDNA concentrations. The work positions this as a whole-blood boundary analysis to identify limiting interface configurations and operating conditions.

Significance. If the model accurately represents the combined physical effects, the result would be significant for guiding nanosensor design in intrabody nanonetworks by quantifying how Debye screening, charge separation, and noise limit reliable low-concentration ctDNA detection in whole blood. The Monte Carlo approach with grounded parameters allows exploration of the relevant physics and highlights specific barriers (e.g., attenuation and fluctuation margins) that could inform future experimental efforts in label-free intravascular sensing.

major comments (1)
  1. [Abstract and Model Description] Abstract and Model Description: The central claim that current shifts do not reliably exceed the blank-derived threshold at low ctDNA concentrations rests on the fidelity of the reduced-order stochastic model in combining Debye-screened charge transduction, finite-capacity binding, nonspecific adsorption, background fluctuations, and electronic noise. The manuscript states that parameters are 'physiologically grounded' but provides no direct comparison of simulated versus measured whole-blood transfer curves, noise spectra, or sensitivity analysis; if the model underestimates signal attenuation (e.g., via charge-to-channel distance) or overestimates low-frequency noise, the margin between target and blank distributions would increase and the headline boundary conclusion could reverse. This validation gap is load-bearing for the reported result.
minor comments (2)
  1. [Abstract] The abstract would benefit from explicitly stating the range of ctDNA concentrations and number of Monte Carlo runs used in the evaluation.
  2. Consider adding a table or appendix listing all physiologically grounded parameters with their literature sources and any assumed distributions for the stochastic components.

Simulated Author's Rebuttal

1 responses · 1 unresolved

We thank the referee for their thorough review and for recognizing the potential significance of our work in guiding nanosensor design. We provide a point-by-point response to the major comment below.

read point-by-point responses

  1. Referee: [Abstract and Model Description] Abstract and Model Description: The central claim that current shifts do not reliably exceed the blank-derived threshold at low ctDNA concentrations rests on the fidelity of the reduced-order stochastic model in combining Debye-screened charge transduction, finite-capacity binding, nonspecific adsorption, background fluctuations, and electronic noise. The manuscript states that parameters are 'physiologically grounded' but provides no direct comparison of simulated versus measured whole-blood transfer curves, noise spectra, or sensitivity analysis; if the model underestimates signal attenuation (e.g., via charge-to-channel distance) or overestimates low-frequency noise, the margin between target and blank distributions would increase and the headline boundary conclusion could reverse. This validation gap is load-bearing for the reported result.

    Authors: We agree that the absence of direct experimental validation in whole blood represents a limitation for interpreting the quantitative margins. Our manuscript presents a reduced-order stochastic model as a boundary analysis tool, using parameters sourced from the literature on BioFET operation in physiological environments (e.g., Debye screening lengths in blood plasma, typical biomolecule-to-channel distances in FET biosensors, and noise models from nanoscale electronics). We do not claim the model is calibrated to new whole-blood measurements, as the goal is to highlight fundamental physical constraints that would apply across devices. To address the concern, we will revise the manuscript to include: (1) an expanded table or section detailing the literature sources for each key parameter with specific references, and (2) a sensitivity analysis in which we vary the charge-to-channel separation and the low-frequency noise amplitude over ranges consistent with experimental reports. This will show that the conclusion regarding unreliable detection at low concentrations remains robust unless parameters are set to unrealistically favorable values. We believe this strengthens the presentation without requiring new experimental data. revision: partial

standing simulated objections not resolved
  • Providing direct comparisons between simulated and measured whole-blood transfer curves or noise spectra, since the study is a computational modeling effort without accompanying experimental measurements.

Circularity Check

0 steps flagged

No significant circularity: derivation rests on external physical principles and parameter estimates

full rationale

The paper constructs a reduced-order stochastic simulation that combines Debye screening, finite-capacity binding kinetics, nonspecific adsorption, background fluctuations, and electronic noise under a quasi-static charge-gating regime. Monte Carlo runs then produce the reported current-shift distributions and threshold comparisons. No equations or parameter choices are shown to be defined in terms of the target detection outcome, no fitted subset is relabeled as a prediction, and no self-citation chain is invoked to justify uniqueness or an ansatz. The model therefore remains an independent forward computation whose outputs are not equivalent to its inputs by construction.

Axiom & Free-Parameter Ledger

1 free parameters · 1 axioms · 0 invented entities

The central claim depends on the fidelity of the reduced-order stochastic model and the choice of physiologically grounded parameters for blood-specific effects.

free parameters (1)
  • physiologically grounded parameters
    Used to set values for Debye length, charge-to-channel separation, binding rates, and noise characteristics in the Monte Carlo runs.
axioms (1)
  • domain assumption quasi-static charge-gating regime is representative of operating conditions
    The model evaluation is performed and conclusions drawn under this regime as stated in the abstract.

pith-pipeline@v0.9.0 · 5771 in / 1234 out tokens · 48449 ms · 2026-05-22T03:59:52.349352+00:00 · methodology

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.

Reference graph

Works this paper leans on

41 extracted references · 41 canonical work pages

  1. [1]

    Jae-Hyuk Ahn et al. 2017. Charge and dielectric effects of biomolecules on electrical characteristics of nanowire FET biosensors.Applied Physics Letters, 111, 113701. doi:10.1063/1.5003106

    work page doi:10.1063/1.5003106 2017

  2. [2]

    I. F. Akyildiz et al. 2015. The internet of Bio-Nano things.IEEE Communications Magazine, 53, 3, 32–40. doi:10.1109/MCOM.2015.7060516. Whole-Blood Boundary Analysis of BioFET-Based ctDNA Detection for Intravascular Sensing in Intrabody Nanonetworks NanoCom ’26, September 21–23, 2026, St. John’s, Canada

    work page doi:10.1109/mcom.2015.7060516 2015

  3. [3]

    Shubham Babbar et al. 2026. Reassessing the challenge of Debye length in field-effect biosensors.Chemical Engineering Journal, 527, 172070. doi:10.1016/j .cej.2025.172070

    work page doi:10.1016/j 2026

  4. [4]

    Chetan Bettegowda et al. 2014. Detection of circulating tumor DNA in early- and late-stage human malignancies.Science Translational Medicine, 6, 224, 224ra24–224ra24. eprint: https://www.science.org/doi/pdf/10.1126/scitranslme d.3007094. doi:10.1126/scitranslmed.3007094

    work page doi:10.1126/scitranslme 2014

  5. [5]

    Bittla et al

    P. Bittla et al. 2023. Exploring circulating tumor DNA (ctDNA) and its role in early detection of cancer: a systematic review.Cureus, 15, 9, (Sept. 2023), e45784. doi:10.7759/cureus.45784

    work page doi:10.7759/cureus.45784 2023

  6. [6]

    Duo Chen et al. 2024. Nanostructured interface-engineered field-effect tran- sistor biosensors for sensitive detection of serum miRNAs.The Innovation Materials, 2, 4, 100091. doi:10.59717/j.xinn-mater.2024.100091

    work page doi:10.59717/j.xinn-mater.2024.100091 2024

  7. [7]

    Chen et al

    H. Chen et al. 2019. A new biosensor detection system to overcome the Debye screening effect: dialysis-silicon nanowire field effect transistor.International Journal of Nanomedicine, 14, (Apr. 2019), 2985–2993. doi:10.2147/IJN.S198734

    work page doi:10.2147/ijn.s198734 2019

  8. [8]

    Tim Cholko, Shivansh Kaushik, and Chia-En A. Chang. 2019. Dynamics and molecular interactions of single-stranded DNA in nucleic acid biosensors with varied surface properties.Physical Chemistry Chemical Physics, 21. doi:10.1039 /C9CP02441G

    work page 2019

  9. [9]

    Chia-Ho Chu et al. 2017. Beyond the Debye length in high ionic strength solution: direct protein detection with field-effect transistors (FETs) in human serum.Scientific Reports, 7, 1, 5256. doi:10.1038/s41598-017-05426-6

    work page doi:10.1038/s41598-017-05426-6 2017

  10. [10]

    Crosby et al

    D. Crosby et al. 2022. Early detection of cancer.Science, 375, eaay9040. doi:10.1 126/science.aay9040

    work page 2022

  11. [11]

    Luca De Vico et al. 2011. Predicting and rationalizing the effect of surface charge distribution and orientation on nano-wire based FET bio-sensors.Nanoscale, 3, 9, 3635–3640. doi:10.1039/C1NR10316D

    work page doi:10.1039/c1nr10316d 2011

  12. [12]

    Jamal Deen et al

    M. Jamal Deen et al. 2006. Noise considerations in field-effect biosensors.Jour- nal of Applied Physics, 100, 7, 074703. doi:10.1063/1.2355542

    work page doi:10.1063/1.2355542 2006

  13. [13]

    Downs and Kevin W

    Alex M. Downs and Kevin W. Plaxco. 2022. Real-time, in-vivo molecular moni- toring using electrochemical aptamer-based sensors: opportunities and chal- lenges.ACS Sensors, 7, 10, 2823–2832. doi:10.1021/acssensors.2c01428

    work page doi:10.1021/acssensors.2c01428 2022

  14. [14]

    Andreas Frutiger et al. 2021. Nonspecific binding—fundamental concepts and consequences for biosensing applications.Chemical Reviews, 121, 13, 8095–8160. doi:10.1021/acs.chemrev.1c00044

    work page doi:10.1021/acs.chemrev.1c00044 2021

  15. [15]

    Ning Gao et al. 2015. General strategy for biodetection in high ionic strength solutions using transistor-based nanoelectronic sensors.Nano Letters, 15, 3, 2143–2148. doi:10.1021/acs.nanolett.5b00133

    work page doi:10.1021/acs.nanolett.5b00133 2015

  16. [16]

    Lusine Gasparyan, Ferdinand Gasparyan, and Vahan Simonyan. 2021. Internal electrical noises of BioFET sensors based on various architectures.Open Journal of Biophysics, 11, (Jan. 2021), 177–204. doi:10.4236/ojbiphy.2021.112006

    work page doi:10.4236/ojbiphy.2021.112006 2021

  17. [17]

    Josephs and Tao Ye

    Eric A. Josephs and Tao Ye. 2012. Electric-field dependent conformations of single DNA molecules on a model biosensor surface.Nano Letters, 12, 10, 5255–

    work page 2012

  18. [18]

    doi:10.1021/nl3024356

    work page doi:10.1021/nl3024356

  19. [19]

    Vladimir Kesler, Boris Murmann, and H. Tom Soh. 2020. Going beyond the Debye length: overcoming charge screening limitations in next-generation bioelectronic sensors.ACS Nano, 14, 12, 16194–16201. doi:10.1021/acsnano.0c0 8622

    work page doi:10.1021/acsnano.0c0 2020

  20. [20]

    Dujuan Li et al. 2021. A supersensitive silicon nanowire array biosensor for quantitating tumor marker ctDNA.Biosensors and Bioelectronics, 181, 113147. doi:10.1016/j.bios.2021.113147

    work page doi:10.1016/j.bios.2021.113147 2021

  21. [21]

    Liang et al

    X. Liang et al. 2025. Liquid biopsy: a breakthrough technology in early cancer screening.Cancer Screening and Prevention, 4, 1, 40–52. doi:10.14218/CSP.2024 .00031

    work page doi:10.14218/csp.2024 2025

  22. [22]

    Benjamin Lowe et al. 2017. Field-effect sensors – from pH sensing to biosensing: sensitivity enhancement using streptavidin-biotin as a model system.The Analyst, 142. doi:10.1039/C7AN00455A

    work page doi:10.1039/c7an00455a 2017

  23. [23]

    Liwei Ma et al. 2024. Liquid biopsy in cancer: current status, challenges and future prospects.Signal Transduction and Targeted Therapy, 9, 1, (Dec. 2024),

    work page 2024

  24. [24]

    doi:10.1038/s41392-024-02021-w

    work page doi:10.1038/s41392-024-02021-w

  25. [25]

    Carlos Augusto Bergfeld Mori et al. 2022. Signal to noise ratio in nanoscale BioFETs.Solid-State Electronics, 194, 108358. doi:10.1016/j.sse.2022.108358

    work page doi:10.1016/j.sse.2022.108358 2022

  26. [26]

    Jacopo Movilli et al. 2018. Control of probe density at DNA biosensor surfaces using poly(l-lysine) with appended reactive groups.Bioconjugate Chemistry, 29, 12, 4110–4118. doi:10.1021/acs.bioconjchem.8b00733

    work page doi:10.1021/acs.bioconjchem.8b00733 2018

  27. [27]

    Xia Peng et al. 2025. Signal-to-noise enhanced detection of circulating tumor DNA via rolling circle amplification and amphiphilic polymer-integrated field- effect transistor sensors.Microchemical Journal, 217, 114981. doi:10.1016/j.micr oc.2025.114981

    work page doi:10.1016/j.micr 2025

  28. [28]

    Toshiya Sakata. 2024. Signal transduction interfaces for field-effect transistor- based biosensors.Communications Chemistry, 7, 1, 35. doi:10.1038/s42004-024- 01121-6

    work page doi:10.1038/s42004-024- 2024

  29. [29]

    Soumadri Samanta et al. 2026. Biological transistors for direct biosensing of L-Dopa in ultrasmall samples of unprocessed and unwashed whole blood.ACS Sensors, 11, 1, 107–118. doi:10.1021/acssensors.5c02466

    work page doi:10.1021/acssensors.5c02466 2026

  30. [30]

    Jiping Shi et al. 2020. Size profile of cell-free DNA: a beacon guiding the practice and innovation of clinical testing.Theranostics, 10, 11, 4737–4748. doi:10.7150/t hno.42565

    work page doi:10.7150/t 2020

  31. [31]

    Ethungshan Shitiri et al. 2024. Work-in-progress: intra-body nanonetworks for in vivo biomarker detection in capillaries. InProceedings of the 11th Annual ACM International Conference on Nanoscale Computing and Communication (NANOCOM ’24). Association for Computing Machinery, Milan, Italy, 134–135. isbn: 9798400711718. doi:10.1145/3686015.3689424

    work page doi:10.1145/3686015.3689424 2024

  32. [32]

    Giulia Siravegna et al. 2017. Integrating liquid biopsies into the management of cancer.Nature Reviews Clinical Oncology, 14, 9, 531–548

    work page 2017

  33. [33]

    Eric Stern et al. 2010. Label-free biomarker detection from whole blood.Nature Nanotechnology, 5, 2, 138–142. doi:10.1038/nnano.2009.353

    work page doi:10.1038/nnano.2009.353 2010

  34. [34]

    Mohamad T. 2018. Limit of Blank (LOB), Limit of Detection (LOD), and Limit of Quantification (LOQ).Organic & Medicinal Chemistry International Journal, 7, 5, 555722. doi:10.19080/OMCIJ.2018.07.555722

    work page doi:10.19080/omcij.2018.07.555722 2018

  35. [35]

    Wen et al

    X. Wen et al. 2022. Circulating tumor DNA–a novel biomarker of tumor pro- gression and its favorable detection techniques.Cancers, 14, 24, 6025. doi:10.33 90/cancers14246025

    work page 2022

  36. [36]

    World Health Organization. 2025. Cancer. [Accessed: 13-Feb-2026]. https://ww w.who.int/health-topics/cancer#tab=tab_1

    work page 2025

  37. [37]

    Jie Wu et al. 2023. Device integration of electrochemical biosensors.Nature Reviews Bioengineering, 1, 5, 346–360. doi:10.1038/s44222-023-00032-w

    work page doi:10.1038/s44222-023-00032-w 2023

  38. [38]

    Jian Xu and Hyowon Lee. 2020. Anti-biofouling strategies for long-term con- tinuous use of implantable biosensors.Chemosensors, 8, 3, 66. doi:10.3390/che mosensors8030066

    work page doi:10.3390/che 2020

  39. [39]

    Shicai Xu et al. 2017. Real-time reliable determination of binding kinetics of DNA hybridization using a multi-channel graphene biosensor.Nature Commu- nications, 8, 14902. doi:10.1038/ncomms14902

    work page doi:10.1038/ncomms14902 2017

  40. [40]

    Kexin Yi et al. 2023. Emerging ctDNA detection strategies in clinical cancer theranostics.Smart Medicine, 2, 4, e20230031. doi:10.1002/SMMD.20230031

    work page doi:10.1002/smmd.20230031 2023

  41. [41]

    Jingcheng Zhou et al. 2022. A fiber optic photoacoustic sensor for real-time heparin monitoring.Biosensors and Bioelectronics, 196, 113692. doi:10.1016/j.bi os.2021.113692

    work page doi:10.1016/j.bi 2022